Sagimet's Partner Reports Positive Long-Term Phase 3 Acne Data & China NDA Acceptance for Denifanstat

summarizeSummary

Sagimet Biosciences announced positive long-term Phase 3 clinical trial results for denifanstat in acne from its partner Ascletis Pharma, alongside the acceptance of the drug's NDA in China, validating its FASN inhibition platform.

check_boxKey Events

• Positive Long-Term Phase 3 Acne Trial Results

  Sagimet's partner, Ascletis Pharma, reported positive topline results from a 52-week open-label Phase 3 clinical trial of denifanstat (ASC40) for moderate to severe acne, demonstrating general tolerability and sustained efficacy improvements.

• China NDA Acceptance for Denifanstat in Acne

  Ascletis Pharma's New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne was accepted by China's National Medical Products Administration (NMPA) in December 2025.

• MASH Combination Therapy Progress

  The company completed a Phase 1 pharmacokinetic (PK) clinical trial for a combination of denifanstat and resmetirom for MASH, with a Phase 2 trial in MASH cirrhosis (F4) patients planned to initiate in 2H 2026.

• Second FASN Inhibitor in Clinic

  Sagimet's second oral FASN inhibitor, TVB-3567, initiated a Phase 1 first-in-human clinical trial in June 2025 for the development of an acne indication.

auto_awesomeAnalysis

Sagimet Biosciences announced positive long-term safety and sustained efficacy results from its partner Ascletis Pharma's open-label Phase 3 clinical trial of denifanstat (ASC40) for moderate to severe acne in China. This trial, an extension of a previously successful 12-week study, demonstrated denifanstat was generally well-tolerated over 52 weeks with continued efficacy improvements. The news also highlights Ascletis's NDA acceptance by China NMPA in December 2025, marking significant regulatory progress for denifanstat in acne. While the trial is by a partner and for a specific region/indication, these results validate the FASN inhibition mechanism, which is central to Sagimet's pipeline, including its lead MASH program. The filing also provided updates on the MASH combination therapy (Phase 1 PK completed, Phase 2 planned for 2H 2026) and TVB-3567 (Phase 1 initiated), reinforcing overall pipeline momentum.